ZyVersa’s IC 100 shows promise in OAC treatment study

WESTON, Fla. - ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA), a clinical-stage biopharmaceutical company with a current market capitalization of $1.85 million, has published new data in the Journal of the American Heart Association indicating that its Inflammasome ASC Inhibitor IC 100 may be an effective treatment for obesity-associated cardiomyopathy (OAC). According to InvestingPro data, the company’s stock has experienced significant volatility, currently trading at $0.79, near its 52-week low of $0.75.

OAC is a condition where the heart muscle becomes abnormally enlarged and inflamed, leading to a decreased ability to pump blood and a five-year survival rate of less than 50%. The study, conducted using a diet-induced obesity cardiomyopathy mouse model, suggests that inhibiting the NLRP3 inflammasome with IC 100 can attenuate the progression of OAC.

Key findings from the research showed that IC 100 reduced body weight, fasting blood glucose, and cardiac inflammation in obese mice. It also prevented myocardial hypertrophy, fibrosis, and dysfunction, while restoring maximal oxygen consumption rates. Additionally, IC 100 attenuated cardiac lipid accumulation which is known to promote the progression of heart failure in obesity.

IC 100 is a novel humanized IgG4 monoclonal antibody that targets the ASC component of inflammasomes, which are implicated in various cardiovascular diseases. By inhibiting the formation of inflammasomes, IC 100 blocks the activation of IL-1β, a pro-inflammatory cytokine involved in the inflammatory response.

Stephen C. Glover, Co-founder, Chairman, CEO, and President of ZyVersa, stated that the data support the potential of IC 100 as a therapeutic option for patients with obesity and its associated cardiovascular comorbidities. He emphasized the drug’s ability to inhibit multiple inflammasomes, which may lead to better control of inflammation than targeting a single inflammasome. Despite challenging financial metrics, including an EBITDA of -$9.62 million in the last twelve months, InvestingPro analysts maintain a bullish stance with a $20 price target.

ZyVersa is focused on addressing high unmet medical needs and is positioned in the inflammasome space with IC 100. The company is also developing treatments for kidney diseases, including a phase 2 Cholesterol Efflux Mediator™ VAR 200 for focal segmental glomerulosclerosis (FSGS). Investors seeking deeper insights into ZyVersa’s financial health and growth potential can access additional analysis and 12 more exclusive ProTips through InvestingPro, including detailed profitability metrics and cash flow analysis.

The information reported is based on a press release statement from ZyVersa Therapeutics, Inc.

In other recent news, ZyVersa Therapeutics, Inc. has announced promising results from studies involving its Inflammasome ASC Inhibitor IC 100, which could offer new treatment options for Alzheimer’s disease and heart failure with preserved ejection fraction (HFpEF). The Alzheimer’s research, published in the journal Immunity, showed that inhibiting the NLRP3 inflammasome reduced inflammation and enhanced the degradation of amyloid beta plaques in a mouse model. Additionally, a study in Biomedicine & Pharmacotherapy highlighted IC 100’s cardioprotective effects in an obese animal model, demonstrating reduced inflammation and improved metabolic parameters. ZyVersa has also secured $2 million in funding through a financing agreement with a U.S. institutional investor, aimed at supporting its drug development initiatives. The deal involves the sale of over 2 million shares and warrants, which are priced at $0.95 per share and exercisable at $1.00 per share. A.G.P./Alliance Global Partners is acting as the sole placement agent for this transaction. The company plans to file a registration statement for the resale of these securities shortly after their annual report submission. ZyVersa continues to focus on developing drugs for inflammatory and renal diseases, with a significant market potential for its products.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.